We recently published a list of the 10 Best High Short Interest Stocks to Buy Now. In this article, we are going to take a ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2025 it granted stock options to purchase an ...

H.C. Wainwright reiterates Cytokinetics (CYTK) as a top pick after Bristol-Myers (BMY) announced that the Phase 3 ODYSSEY-HCM clinical trial ...

Cytokinetics (CYTK) stock rises and rival Edgewise (EWTX) stock drops as the latter posts mixed Phase 2 trial data for its heart disorder therapy EDG-7500. Read more here.

Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.

Vanguard Group Inc. raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.3% in the fourth quarter, according to the company in its most recent filing with the ...

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to ...

Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb's ...

California Public Employees Retirement System trimmed its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – ...

Edgewise Therapeutics shares tumbled more than 20% Wednesday after the developmental drug company issued the results of its latest clinical trial.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to ...